07:00 , Oct 8, 2015 |  BC Innovations  |  Product R&D

Medicines Co.'s double play

While inhibiting β-lactamases is one of the dominant strategies for combating antibiotic resistance, companies have only had success targeting one of the two classes of the enzyme, serine β-lactamases, and have made little progress against...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

GlaxoSmithKline pharmaceuticals news

GlaxoSmithKline said it will invest about £200 million ($327.4 million) for manufacturing in the U.K. The pharma said it will build new manufacturing facilities at its Ware site and a new bulk sterile building and...
03:11 , Dec 12, 2013 |  BC Extra  |  Company News

GSK investing additional L200M in U.K. manufacturing

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will invest about L200 million ($327.4 million) for manufacturing in the U.K. The pharma said it will build new manufacturing facilities at its Ware site as well as a...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

American Society of Clinical Oncology (ASCO) regulatory update

ASCO issued a clinical practice guideline to manage neutropenia with fever and prevent related infections in patients with cancer. The guideline for adult patients specifically recommends preventive treatment with antibacterial and antifungal drugs - preferably...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Dr. Reddy's, GlaxoSmithKline deal

Dr. Reddy completed its previously announced acquisition of GlaxoSmithKline's penicillin manufacturing site in Bristol, Tenn., and U.S. rights to Augmentin amoxicillin/clavulanate and Amoxil amoxicillin. Further terms were not disclosed (see BioCentury, Dec. 6, 2010). Dr. Reddy's...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

Dr. Reddy's, GlaxoSmithKline deal

GlaxoSmithKline will transfer ownership of its penicillin manufacturing site in Bristol, Tenn., and U.S. rights to Augmentin amoxicillin/clavulanate and Amoxil amoxicillin to Dr. Reddy's. GSK will retain ex-U.S. rights for the products. The deal is...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Clinical News

Amoxicillin clavulanate regulatory update

Ranbaxy's Ohm Laboratories Inc. unit received a warning letter from FDA citing certain current good manufacturing practices (cGMP) violations at the company's liquid manufacturing facility in Gloversville, N.Y. The letter was issued based on results...
07:00 , Mar 12, 2009 |  BC Innovations  |  Targets & Mechanisms

Ganging up on TB

Work by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that two FDA-approved antibiotics-meropenem and clavulanate-could be used in combination to overcome drug-resistant Mycobacterium tuberculosis.1 Although the fact that meropenem must be...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease ...
08:00 , Dec 17, 2007 |  BioCentury  |  Finance

Ebb & Flow

Dashing the hopes of buysiders, Biogen Idec (BIIB) said it had not received any definitive offers and would remain independent. The announcement came after market close on Wednesday and BIIB plunged $17.97 (24%) to $57.91...